Open-Label Extension of Pimavanserin for Agitation and Aggression in Alzheimer ' s

Language
UndefinedPurpose:To evaluate the safety and tolerability of pimavanserin (Nuplazid™) as a treatment for agitation and aggression in adults with probable Alzheimer's disease .

Source: Alzheimers Clinical Trials - June 22, 2017 Category: Geriatrics Authors: jharper Source Type: clinical trials